Monopar Therapeutics Inc.

NASDAQ (USD): Monopar Therapeutics Inc. (MNPR)

Last Price

4.75

Today's Change

+0.14 (3.03%)

Day's Change

4.52 - 4.95

Trading Volume

55,394

Overview

Market Cap

16 Million

Shares Outstanding

3 Million

Avg Volume

815,916

Avg Price (50 Days)

3.40

Avg Price (200 Days)

3.26

PE Ratio

-2.08

EPS

-2.30

Earnings Announcement

07-Nov-2024

Previous Close

4.61

Open

4.52

Day's Range

4.52 - 4.95

Year Range

1.37 - 8.65

Trading Volume

57,661

Price Change Highlight

1 Day Change

3.94%

5 Day Change

-1.84%

1 Month Change

100.42%

3 Month Change

33.06%

6 Month Change

59.14%

Ytd Change

158.92%

1 Year Change

75.46%

3 Year Change

-79.26%

5 Year Change

-96.38%

10 Year Change

-96.38%

Max Change

-96.38%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment